International audience ; Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
International audience ; Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
International audience ; Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
International audience ; Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. ; European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon ; Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England ; UPMC Paris 06, Sorbonne Univ,Dept Pneumol & Addictol,UMR S 1136, Hop Arnaud de Villeneuve,CHRU Montpellier, IPLESP,Equipe EPAR,Unite Allergol, F-75013 Paris, France ; Univ S Florida, Morsani Coll Med, Tampa, FL USA ; Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland ; Univ Hosp Ghent, ENT Dept, Upper Airways Res Lab URL, Ghent, Belgium ; IQ4U Consultants Ltd, London, England ; Osped Riuniti, Univ Hosp, Allergy Unit, Dept Internal Med, Ancona, Italy ; Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria ; Univ Naples 2, Rome, Italy ; CNR, IFT, Rome, Italy ; Univ Genoa, Allergy & Resp Dis Clin, DIMI, IRCCS AOU San Martino IST, Genoa, Italy ; Hosp Univ Vall dHebron, Allergy Sect, Dept Internal Med, Barcelona, Spain ; Montpellier UPMC Univ Paris 06, Sorbonne Univ,UMRS 1136, Hop Arnaud de Villeneuve,Equipe EPAR IPLESP, Div Allergy,Dept Pulmonol,Univ Hosp Montpellier, Paris, France ; Nova Southeastern Univ, Ft Lauderdale, FL USA ; Univ Hosp Strasbourg, Div Allergy, Chest Dis Dept, Strasbourg, France ; Univ Versailles St Quentin, Suresnes, France ; Foch Hosp, Dept Airway Dis, Clin Pharmacol Unit, UPRES EA 220, Suresnes, France ; Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France ; Univ Palermo, Di Bi MIS, Palermo, Italy ; Kings Coll London, Guys & St Thomas NHS Trust, London, England ; Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England ; Childrens Hosp, Dept Pediat Pulmonol & Allergy, Aarau, Switzerland ; Bambino Gesu Pediat Hosp, Dept Pediat, Div Allergy, Rome, Italy ; Kings Coll London, Allergy Acad, London, England ; Erasmus MC, Dept Internal Med, Bldg Rochussenstr, Rotterdam, Netherlands ; Hosp San Bernardo, Unidad Alergia & Asma, Salta, Argentina ; Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland ; Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark ; Katholieke Univ Leuven, Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium ; Secretary Immunotherapy Interest Grp EAACI, Allergy Learning & Consulting, Copenhagen, Denmark ; UPMC Univ Paris, Sorbonne Univ,Hop Enfants Armand Trousseau,INSERM, Inst Pierre Louis Epidemiol & Sante Publ,Equipe E, Allergol Dept,Ctr Asthme & Allergies,UMR S 1136, Paris, France ; Hosp Sirio Libanes, Sao Paulo, Brazil ; Univ Hosp Montpellier, Montpellier, France ; UPMC Paris 06, Sorbonne Univ, Equipe EPAR, UMR S 1136,IPLESP, Paris, France ; Ackermann Hanf & Kleine Tebbe, Outpatient Clin & Clin Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany ; German Soc Otorhinolaryngol HNS, Ctr Rhinol & Allergol, Wiesbaden, Germany ; Univ Med Ctr Utrecht, Dept Immunol & Dermatol Allergol, Utrecht, Netherlands ; Med Univ Lodz, Lodz, Poland ; ARIA, Mexico City, DF, Mexico ; Hosp Med Sur, AAAAI, Mexico City, DF, Mexico ; Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark ; Rigshosp, Dept Clin Expt Res, Copenhagen, Denmark ; Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark ; Charite Med Univ, Pediat Pneumol & Immunol, Berlin, Germany ; Gentofte Univ Hosp, Allergy Clin, Danish Allergy Ctr, Hellerup, Denmark ; Klinikum Univ Koln AoR, IMSIE, Cologne, Germany ; Hosp Clin Barcelona, Unitat Rinol & Clin Olfacte, ENT Dept, Clin & Expt Resp Immunoallergy,IDIBAPS,CIBERES, Barcelona, Catalonia, Spain ; Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy ; Univ Athens, Allergy Unit, Pediat Clin 2, Athens, Greece ; Univ Genoa, Allergy & Resp Dis, IRCCS San Martino IST, Genoa, Italy ; ASST Grande Osped Metropolitano Niguarda, Pzza Osped Maggiore, Milan, Italy ; Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany ; Heidelberg Univ, Med Fac Mannheim, Heidelberg, Germany ; Ctr Rhinol & Allergol, Wiesbaden, Germany ; Univ Aberdeen, Acad Primary Care, Div Appl Hlth Sci, Primary Care Resp Med, Aberdeen, Scotland ; RiRL, Cambridge, England ; Optimum Patient Care Ltd, Singapore, Singapore ; Hosp Infantil Univ Nino Jesus, Allergy Sect, Madrid, Spain ; Ludwig Maximillian Univ, Dept Dermatol & Allergol, Munich, Germany ; Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland ; Royal Natl Throat Nose & Ear Hosp, London, England ; UCL, London, England ; Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland ; Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev Sec, Immunomodulat & Tolerance Grp,Fac Med, London, England ; MRC, London, England ; Asthma UK Ctr Allerg Mechanisms Asthma, London, England ; Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Asthma UK Ctr Appl Res, Med Informat Ctr, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland ; SLAAI, Asuncion, Paraguay ; Univ Fed Sao Paulo, Programa Posgrad Pediat & Ciencias Aplicadas Pedi, Dept Pediat EPM, Sao Paulo, Brazil ; Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria ; Allergy Outpatient Clin Reumannplatz, Vienna, Austria ; Complejo Hosp Navarra, Serv Alergol, Pamplona, Spain ; Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands ; Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands ; Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Interdisciplinary Dept Med, Bari, Italy ; Complejo Hosp Univ Santiago de Compostela, Dept Allergy, Santiago De Compostela, Spain ; Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria ; Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, Allergie Ctr Charite, Berlin, Germany ; European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron Vleillissement Actif Languedoc Roussi, Paris, France ; INSERM, VIMA, Epidemiol & Publ Hlth Approaches, U1168,Ageing & Chron Dis, Paris, France ; Univ Versailles St Quentin En Yvelines, UVSQ, UMR S 1168, Versailles, France ; CHRU, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France ; Programa de Pòs‑Graduação em Pediatria e Ciências Aplicadas à Pediatria, Departamento de Pediatria EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil ; Web of Science
In: Calderon , M A , Demoly , P , Casale , T , Akdis , C A , Bachert , C , Bewick , M , Bilò , B M , Bohle , B , Bonini , S , Bush , A , Caimmi , D P , Canonica , G W , Cardona , V , Chiriac , A M , Cox , L , Custovic , A , De Blay , F , Devillier , P , Didier , A , Di Lorenzo , G , Du Toit , G , Durham , S R , Eng , P , Fiocchi , A , Fox , A T , van Wijk , R G , Gomez , R M , Haathela , T , Halken , S , Hellings , P W , Jacobsen , L , Just , J , Tanno , L K , Kleine-Tebbe , J , Klimek , L , Knol , E F , Kuna , P , Larenas-Linnemann , D E , Linneberg , A , Matricardi , M , Malling , H J , Moesges , R , Mullol , J , Muraro , A , Papadopoulos , N , Passalacqua , G , Pastorello , E , Pfaar , O , Price , D , Del Rio , P R , Ruëff , R , Samolinski , B , Scadding , G K , Senti , G , Shamji , M H , Sheikh , A , Sisul , J C , Sole , D , Sturm , G J , Tabar , A , Van Ree , R , Ventura , M T , Vidal , C , Varga , E M , Worm , M , Zuberbier , T & Bousquet , J 2016 , ' Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project ' , Clinical and Translational Allergy , vol. 6 , 41 . https://doi.org/10.1186/s13601-016-0131-x
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
International audience ; Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
International audience ; Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
International audience ; Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. ; Peer reviewed
In: Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haathela, T., Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T. and Bousquet, J. (2016). Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clin. Transl. Allergy, 6. LONDON: BMC. ISSN 2045-7022
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
In: Calderon , M A , Demoly , P , Casale , T , Akdis , C A , Bachert , C , Bewick , M , Bilò , B M , Bohle , B , Bonini , S , Bush , A , Caimmi , D P , Canonica , G W , Cardona , V , Chiriac , A M , Cox , L , Custovic , A , De Blay , F , Devillier , P , Didier , A , Di Lorenzo , G , Du Toit , G , Durham , S R , Eng , P , Fiocchi , A , Fox , A T , van Wijk , R G , Gomez , R M , Haathela , T , Halken , S , Hellings , P W , Jacobsen , L , Just , J , Tanno , L K , Kleine-Tebbe , J , Klimek , L , Knol , E F , Kuna , P , Larenas-Linnemann , D E , Linneberg , A , Matricardi , M , Malling , H J , Moesges , R , Mullol , J , Muraro , A , Papadopoulos , N , Passalacqua , G , Pastorello , E , Pfaar , O , Price , D , del Rio , P R , Ruëff , R , Samolinski , B , Scadding , G K , Senti , G , Shamji , M H , Sheikh , A , Sisul , J C , Sole , D , Sturm , G J , Tabar , A , van Ree , R , Ventura , M T , Vidal , C , Varga , E M , Worm , M , Zuberbier , T & Bousquet , J 2016 , ' Allergy immunotherapy across the life cycle to promote active and healthy ageing : From research to policies ' , Clinical and Translational Allergy , vol. 6 , 41 . https://doi.org/10.1186/s13601-016-0131-x
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
